MGI (MGI Tech Co., Ltd. or its subsidiaries, collectively MGI), a company committed to developing core tools and technologies that drive innovation in life sciences, announced a collaboration with Predica Diagnostics, a leading innovator in oncology diagnostics, to develop Predica’s targeted RNA sequencing assays on MGI’s cost-effective next-generation sequencing platforms.
The collaboration aims to revolutionize molecular diagnostics by enabling early cancer detection and facilitating personalized, targeted treatment strategies. By combining Predica Diagnostics’ advanced sequencing tests with MGI’s cutting-edge next-generation sequencing platforms, the initiative promises a rapid, accurate and affordable solution for healthcare providers.
Strengthening precision medicine
Predica Diagnostics, known for its expertise in cervical cancer screening through its proprietary ciRNAseq-based test, CervicaDx, offers unparalleled precision in identifying high-risk HPV oncogenes and other (pre-)malignant biomarkers. By integrating this advanced diagnostic capability with MGI’s robust and affordable DNBSEQ technology, the partnership aims to significantly improve the accuracy and accessibility of diagnostic testing.
Improving affordability and accessibility
A core value of this partnership is to make high-quality diagnostic and predictive testing more affordable and accessible. Known for their cost-effectiveness and scalability, MGI Tech’s DNBSEQ platforms will enable healthcare organizations to offer advanced genomic and transcriptomic testing at a lower cost. Compared to existing NGS-based technologies, MGI’s platform offers cost-effective and faster results. As part of the collaboration, MGI’s NGS platform will be used to perform the final analysis of Predica’s groundbreaking ciRNAseq-based targeted RNA sequencing tests. This combination will help researchers and healthcare professionals better predict patient prognosis and guide treatment with precision medicine.
“Predica welcomes MGI as a partner with expertise that is highly synergistic with Predica’s,” says Dr. William Leenders , CSO of Predica Diagnostics. “As our expertise lies in providing intelligent molecular diagnostic solutions to unmet medical needs, we see the combination with MGI’s sequencing platforms as a perfect fit for customers to obtain clinically important information on gene expression without the need for on-site bioinformatics expertise.”
SOURCE: PRNewswire